TGF-β1/PTEN/PI3K signaling plays a critical role in the anti-proliferation effect of tetrandrine in human colon cancer cells

International Journal of Oncology

Volumn 50, Issue 3, 2017, Pages 1011-1021

  Chen, Qian Zhao ^a   Li, Yang ^a   Shao, Ying ^a   Zeng, Yu Hua ^a   Ren, Wen Yan ^a   Liu, Rong Xing ^a   Zhou, Lin Yun ^a   Hu, Xue Lian ^a,b   Huang, Ming ^a   He, Fang ^a   Sun, Wen Juan ^a   Wu, Ke ^a   He, Bai Cheng ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Anticancer; Colon cancer; PI3K Akt; PTEN; Tetrandrine; TGF 1

Indexed keywords

MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TETRANDRINE; TRANSFORMING GROWTH FACTOR BETA1; ANTINEOPLASTIC AGENT; BENZYLISOQUINOLINE DERIVATIVE; PROTEIN KINASE B; PTEN PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL LEVEL; CELL VIABILITY; COLON CANCER CELL LINE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; DRUG EFFECTS; HCT 116 CELL LINE; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BENZYLISOQUINOLINES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; HCT116 CELLS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 85013067833     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2017.3875     Document Type: Article

References (48)

1. Winder T and Lenz HJ: Molecular predictive and prognostic markers in colon cancer. Cancer Treat Rev 36: 550-556, 2010.
2. Anderson JC and Shaw RD: Update on colon cancer screening: Recent advances and observations in colorectal cancer screening. Curr Gastroenterol Rep 16: 403, 2014.
3. Karanikas M and Esebidis A: Increasing incidence of colon cancer in patients
4. Dinic J, Podolski-Renic A, Stankovic T, Bankovic J and Pesic M: New approaches with natural product drugs for overcoming multidrug resistance in cancer Curr Pharm Des 21: 5589-5604, 2015.
5. Chazin EL, Reis RR, Junior WT, Moor LF and Vasconcelos TR: An overview on the development of new potentially active camptothecin analogs against cancer. Mini Rev Med Chem 14: 953-962, 2014.
6. Baird RD, Tan DS and Kaye SB: Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol 7: 575-582, 2010.
7. Xie X, Tang B, Zhou J, Gao Q and Zhang P: Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine. Oncol Rep 30: 773-782, 2013.
8. Qin R, Shen H, Cao Y, Fang Y, Li H, Chen Q and Xu W: Tetrandrine induces mitochondria-mediated apoptosis in human gastric cancer BGC-823 cells. PLoS One 8: e76486, 2013.
9. Lin YC, Chang CW and Wu CR: Anti-nociceptive, anti-inflammatory and toxicological evaluation of Fang-Ji-Huang-Qi-Tang in rodents. BMC Complement Altern Med 15: 10, 2015.
10. Ho LJ, Juan TY, Chao P, Wu WL, Chang DM, Chang SY and Lai JH: Plant alkaloid tetrandrine downregulates IkappaBalpha kinases-IkappaBalpha-NF-kappaB signaling pathway in human peripheral blood T cell. Br J Pharmacol 143: 919-927, 2004.
11. Zhang J, Yu B, Zhang XQ, Sheng ZF, Li SJ, Wang ZJ, Cui XY, Cui SY and Zhang YH: Tetrandrine, an antihypertensive alkaloid, improves the sleep state of spontaneously hypertensive rats (SHRs). J Ethnopharmacol 151: 729-732, 2014.
12. Kou B, Liu W, He W, Zhang Y, Zheng J, Yan Y, Zhang Y, Xu S and Wang H: Tetrandrine suppresses metastatic phenotype of prostate cancer cells by regulating Akt/mTOR/MMP-9 signaling pathway. Oncol Rep 35: 2880-2886, 2016.
13. Lin Y, Wang Y, Liu X, Yan J, Su L and Liu X: A novel derivative of tetrandrine (H1) induces endoplasmic reticulum stress-mediated apoptosis and prosurvival autophagy in human non-small cell lung cancer cells. Tumour Biol 37: 10403-10413, 2016.
14. Wu K, Zhou M, Wu QX, Yuan SX, Wang DX, Jin JL, Huang J, Yang JQ, Sun WJ, Wan LH, et al: The role of IGFBP-5 in mediating the anti-proliferation effect of tetrandrine in human colon cancer cells. Int J Oncol 46: 1205-1213, 2015.
15. Zhang Y, Liu W, He W, Zhang Y, Deng X, Ma Y, Zeng J and Kou B: Tetrandrine reverses epithelial-mesenchymal transition in bladder cancer by downregulating Gli-1. Int J Oncol 48: 2035-2042, 2016.
16. Wei N, Liu GT, Chen XG, Liu Q, Wang FP and Sun H: H1, a derivative of Tetrandrine, exerts anti-MDR activity by initiating intrinsic apoptosis pathway and inhibiting the activation of Erk1/2 and Akt1/2. Biochem Pharmacol 82: 1593-1603, 2011.
17. Dang Y, Xu Y, Wu W, Li W, Sun Y, Yang J, Zhu Y and Zhang C: Tetrandrine suppresses lipopolysaccharide-induced microglial activation by inhibiting NF-κB and ERK signaling pathways in BV2 cells. PLoS One 9: e102522, 2014.
18. Meng LH, Zhang H, Hayward L, Takemura H, Shao RG and Pommier Y: Tetrandrine induces early G1 arrest in human colon carcinoma cells by down-regulating the activity and inducing the degradation of G1-S-specific cyclin-dependent kinases and by inducing p53 and p21Cip1. Cancer Res 64: 9086-9092, 2004.
19. He BC, Gao JL, Zhang BQ, Luo Q, Shi Q, Kim SH, Huang E, Gao Y, Yang K, Wagner ER, et al: Tetrandrine inhibits Wnt/β-catenin signaling and suppresses tumor growth of human colorectal cancer. Mol Pharmacol 79: 211-219, 2011.
20. Bellomo C, Caja L and Moustakas A: Transforming growth factor β as regulator of cancer stemness and metastasis. Br J Cancer 115: 761-769, 2016.
21. Lampropoulos P, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N and Papavassiliou AG: TGF-beta signalling in colon carcinogenesis. Cancer Lett 314: 1-7, 2012.
22. Zarzynska JM: Two faces of TGF-beta1 in breast cancer. Mediators Inflamm 2014: 141747, 2014.
23. Ouhtit A, Madani S, Gupta I, Shanmuganathan S, Abdraboh ME, Al-Riyami H, Al-Farsi YM and Raj MH: TGF-β2: A novel target of CD44-promoted breast cancer invasion. J Cancer 4: 566-572, 2013.
24. Laverty HG, Wakefield LM, Occleston NL, O'Kane S and Ferguson MW: TGF-beta3 and cancer: A review. Cytokine Growth Factor Rev 20: 305-317, 2009.
25. Yu M, Trobridge P, Wang Y, Kanngurn S, Morris SM, Knoblaugh S and Grady WM: Inactivation of TGF-β signaling and loss of PTEN cooperate to induce colon cancer in vivo. Oncogene 33: 1538-1547, 2014.
26. Slattery ML, Herrick JS, Lundgreen A and Wolff RK: Genetic variation in the TGF-β signaling pathway and colon and rectal cancer risk. Cancer Epidemiol Biomarkers Prev 20: 57-69, 2011.
27. Kim YH, Kim G, Kwon CI, Kim JW, Park PW and Hahm KB: TWIST1 and SNAI1 as markers of poor prognosis in human colorectal cancer are associated with the expression of ALDH1 and TGF-β1. Oncol Rep 31: 1380-1388, 2014.
28. Principe DR, DeCant B, Staudacher J, Vitello D, Mangan RJ, Wayne EA, Mascarias E, Diaz AM, Bauer J, McKinney RD, et al: Loss of TGFβ signaling promotes colon cancer progression and tumor-Associated inflammation. Oncotarget: Jun 4, 2016 (Epub ahead of print).
29. Zunwen L, Shizhen Z, Dewu L, Yungui M and Pu N: Effect of tetrandrine on the TGF-β-induced smad signal transduction pathway in human hypertrophic scar fibroblasts in vitro. Burns 38: 404-413, 2012.
30. Luo J, Deng ZL, Luo X, Tang N, Song WX, Chen J, Sharff KA, Luu HH, Haydon RC, Kinzler KW, et al: A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2: 1236-1247, 2007.
31. Chen XL, Ren KH, He HW and Shao RG: Involvement of PI3K/AKT/GSK3beta pathway in tetrandrine-induced G1 arrest and apoptosis. Cancer Biol Ther 7: 1073-1078, 2008.
32. Goldwasser F, Bae I, Fornace AJ Jr and Pommier Y: Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines. Oncol Res 8: 317-323, 1996.
33. Chen MC, Lee NH, Ho TJ, Hsu HH, Kuo CH, Kuo WW, Lin YM, Tsai FJ, Tsai CH and Huang CY: Resistance to irinotecan (CPT-11) activates epidermal growth factor receptor/nuclear factor kappa B and increases cellular metastasis and autophagy in LoVo colon cancer cells. Cancer Lett 349: 51-60, 2014.
34. Bhagya N and Chandrashekar KR: Tetrandrine-A molecule of wide bioactivity. Phytochemistry 125: 5-13, 2016.
35. Watabe T and Miyazono K: Roles of TGF-beta family signaling in stem cell renewal and differentiation. Cell Res 19: 103-115, 2009.
36. Neuzillet C, Tijeras-Raballand A, Cohen R, Cros J, Faivre S, Raymond E and de Gramont A: Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther 147: 22-31, 2015.
37. Fabregat I, Fernando J, Mainez J and Sancho P: TGF-beta signaling in cancer treatment. Curr Pharm Des 20: 2934-2947, 2014.
38. Smith AL, Robin TP and Ford HL: Molecular pathways: Targeting the TGF-β pathway for cancer therapy. Clin Cancer Res 18: 4514-4521, 2012.
39. Morrison CD, Parvani JG and Schiemann WP: The relevance of the TGF-β Paradox to EMT-MET programs. Cancer Lett 341: 30-40, 2013.
40. Mancino M, Strizzi L, Wechselberger C, Watanabe K, Gonzales M, Hamada S, Normanno N, Salomon DS and Bianco C: Regulation of human Cripto-1 gene expression by TGF-beta1 and BMP-4 in embryonal and colon cancer cells. J Cell Physiol 215: 192-203, 2008.
41. Han S, Bui NT, Ho MT, Kim YM, Cho M and Shin DB: Dexamethasone inhibits TGF-β1-induced cell migration by regulating the ERK and AKT pathways in human colon cancer cells via CYR61. Cancer Res Treat 48: 1141-1153, 2016.
42. Xu C, Liu W, Chen Z, Wang Y, Xiong Z and Ji Y: Effect of prenatal tetrandrine administration on transforming growth factor-beta1 level in the lung of nitrofen-induced congenital diaphragmatic hernia rat model. J Pediatr Surg 44: 1611-1620, 2009.
43. Guerrero F, Herencia C, Almadin Y, Martvnez-Moreno JM, Montes de Oca A, Rodriguez-Ortiz ME, Diaz-Tocados JM, Canalejo A, Florio M, Lopez I, et al: TGF-β prevents phosphate-induced osteogenesis through inhibition of BMP and Wnt/β-catenin pathways. PLoS One 9: e89179, 2014.
44. Vo BT, Morton D Jr, Komaragiri S, Millena AC, Leath C and Khan SA: TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. Endocrinology 154: 1768-1779, 2013.
45. Stipursky J, Francis D and Gomes FC: Activation of MAPK/PI3K/SMAD pathways by TGF-β(1) controls differentiation of radial glia into astrocytes in vitro. Dev Neurosci 34: 68-81, 2012.
46. Ciuffreda L, Falcone I, Incani UC, Del Curatolo A, Conciatori F, Matteoni S, Vari S, Vaccaro V, Cognetti F and Milella M: PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. Adv Biol Regul 56: 66-80, 2014.
47. Dillon LM and Miller TW: Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets 15: 65-79, 2014.
48. Molinari F and Frattini M: Functions and regulation of the PTEN gene in colorectal cancer. Front Oncol 3: 326, 2014.